Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oribe for CINV prevention in gynecological cancer patients on TC regimen
NCT06007586Phase 3Completed
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Sichuan Cancer Hospital. Started May 2024; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06007586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007586.